



Vandœuvre-lès-Nancy, November 19, 2020 – 8:00 a.m.

Press release

For immediate release

Launch of PsoriaCure, European programme for the treatment of psoriasis.

The international consortium, led by [Temisis](#), pharmaceutical subsidiary of [PAT](#) announces the launch of **PsoriaCure** as part of the European Union's EUROSTARS innovation program. This high-level research collaborative project was ranked 5th out of 378 submitted projects by a committee of experts.

The aim of this three-year program is to discover the mechanism of action of the first-in-class proprietary compound TEM1657 developed by Temisis for the treatment of psoriasis. TEM1657 is the strongest known regulator of the target *NFKBIZ*, a key driver in autoimmune diseases.



The **PsoriaCure** consortium also includes [StratiCELL](#), Belgian subsidiary of PAT, dedicated to understanding skin biology and pioneering discoveries in dermo-cosmetic products, the German company [PharmBioTec](#), expert in the development of candidate medications at the pre-clinical stage, and the academic laboratory [IMoPA-CNRS](#) from University of Lorraine, specialized in inflammatory signaling networks.

The global budget for **PsoriaCure** is 3,2 M€, funded by the European Union up to 1,5 M€ allocated as follows:

In M€	Budget	Funding
Temisis	1,5	0,6
StratiCELL	0,7	0,5
PharmBioTec	0,7	0,4
IMoPA – CNRS	0,3	0,1
Total PsoriaCure	3,2	1,5



FINANCIAL SCHEDULE

Turnover, 2020

March 1st, 2021

CONTACT US

PAT Investor relations department - investisseur@plantadvanced.com

FIN'EXTENSO – Media relations department - Isabelle Aprile - +33 6 17 38 61 78 - i.aprile@finextenso.fr

Find out all the news about PAT plantadvanced.com
and follow us on social networks:



Concerning the group:

Plant Advanced Technologies is specialized in the identification, optimization and production of rare new active plant compounds for cosmetics, pharmaceuticals, nutraceutical and agrochemical markets. Since its creation, the company has developed unique worldwide patented technologies for fast discovery of active molecules and their industrial production while preserving plant biodiversity (Target Binding® and PAT Plant Milking®).

Temisis: wholly-owned subsidiary of PAT, dedicated to the pharmaceutical development of TEM1657, innovative anti-inflammatory compound. The lead compound is currently in the late preclinical stage. temisis.com

StratiCell: wholly-owned subsidiary of PAT specialized in in vitro objectivation tests and in the manufacturing of reconstructed epidermis predicting responses of human skin. This laboratory is strategically positioned to develop alternative tests to animal testing. straticell.com

Plant Advanced Technologies is registered on Euronext Growth™- Paris
ISIN : FR0010785790 - Mnemonic : ALPAT
Reuters ALPAT.PA - Bloomberg : ALPAT : FP

